Analyst Price Target is $15.50
▲ +188.64% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Aprea Therapeutics in the last 3 months. The average price target is $15.50, with a high forecast of $20.00 and a low forecast of $11.00. The average price target represents a 188.64% upside from the last price of $5.37.
Current Consensus is
Buy
The current consensus among 2 contributing investment analysts is to buy stock in Aprea Therapeutics. This Buy consensus rating has held steady for over two years.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Read More